DOP2017000239A - Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia - Google Patents

Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia

Info

Publication number
DOP2017000239A
DOP2017000239A DO2017000239A DO2017000239A DOP2017000239A DO P2017000239 A DOP2017000239 A DO P2017000239A DO 2017000239 A DO2017000239 A DO 2017000239A DO 2017000239 A DO2017000239 A DO 2017000239A DO P2017000239 A DOP2017000239 A DO P2017000239A
Authority
DO
Dominican Republic
Prior art keywords
sensitive
insulin
hypoxia
vesicles
glucose
Prior art date
Application number
DO2017000239A
Other languages
English (en)
Inventor
Gu Zhen
Yu Jicheng
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Publication of DOP2017000239A publication Critical patent/DOP2017000239A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046—Solid microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production

Abstract

Se describe un sistema de suministro de insulina de bucle cerrado. De forma más particular, el sistema de suministro de insulina que ahora se desvela pude comprender vesículas sensibles a glucosa que liberan insulina en respuesta a la hipoxia desencadenada por la reducción enzimática de glucosa. Además o como alternativa a la insulina, el sistema de suministro puede liberar otros agentes de tratamiento de la diabetes, tales como agentes de tratamiento de la diabetes no basados en insulina. Las vesículas pueden prepararse a partir de un polímero sensible a la hipoxia, tal como un ácido hialurónico sensible a la hipoxia (AH-SH). El AH-SH puede comprender grupos hidrofóbicos que pueden reducirse en entornos hipóxicos para formar grupos hidrófilos. Las vesículas pueden cargarse en microagujas y parches de matriz de microagujas para su uso en el tratamiento de la diabetes o para regular de otro modo los niveles de glucosa en sangre en sujetos que necesiten tal tratamiento. (fig. 1a)
DO2017000239A 2015-04-21 2017-10-17 Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia DOP2017000239A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562150622P 2015-04-21 2015-04-21

Publications (1)

Publication Number Publication Date
DOP2017000239A true DOP2017000239A (es) 2018-01-15

Family

ID=57144247

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000239A DOP2017000239A (es) 2015-04-21 2017-10-17 Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia

Country Status (23)

Country Link
US (2) US11191815B2 (es)
EP (2) EP3285750B1 (es)
JP (1) JP6856546B2 (es)
KR (1) KR102624501B1 (es)
CN (2) CN107530296B (es)
AU (2) AU2016252738B2 (es)
BR (1) BR112017022535A2 (es)
CA (1) CA2983289C (es)
CL (1) CL2017002652A1 (es)
CO (1) CO2017011422A2 (es)
DO (1) DOP2017000239A (es)
EC (1) ECSP17073558A (es)
HK (1) HK1245105A1 (es)
IL (1) IL255155A0 (es)
MA (1) MA54623A (es)
MX (1) MX2017013337A (es)
NZ (1) NZ736578A (es)
PE (1) PE20180325A1 (es)
PH (1) PH12017501910A1 (es)
RU (1) RU2719584C2 (es)
SG (1) SG11201708509YA (es)
TN (1) TN2017000439A1 (es)
WO (1) WO2016172320A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201708509YA (en) 2015-04-21 2017-11-29 Univ North Carolina State Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
CN108778248A (zh) 2016-02-19 2018-11-09 北卡罗来纳州立大学 与生理响应性微针递送系统有关的方法和组合物
WO2018085809A1 (en) * 2016-11-07 2018-05-11 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery
WO2018106697A1 (en) * 2016-12-05 2018-06-14 North Carolina State University H 2o 2-responsive nanoparticles and uses thereof
CN110167624B (zh) * 2016-12-05 2021-11-19 北卡罗来纳州立大学 核-壳微针装置及其用途
US11850285B2 (en) 2017-03-07 2023-12-26 North Carolina State University Insulin-responsive glucagon delivery patch
US11096893B2 (en) 2017-06-02 2021-08-24 North Carolina State University Glucose sensitive compositions for drug delivery
JP6482604B2 (ja) * 2017-06-22 2019-03-13 教裕 南郷 外皮内溶解型ニードル及びニードル装置
US11389405B2 (en) 2017-09-18 2022-07-19 North Carolina State University Artificial beta cells and methods of use thereof
EP3694539A4 (en) 2017-10-10 2021-07-14 North Carolina State University GLUCOSE CARRIER INHIBITOR MODIFIED INSULIN FOR THE DELIVERY OF GLUCOSE SENSITIVE INSULIN
EP3713594A4 (en) 2017-11-21 2021-11-03 North Carolina State University LOAD CHANGE POLYMER DEPOSIT FOR DELIVERY OF GLUCOSE-TRIGGERED INSULIN WITH ULTRA-RAPID RESPONSE
CN108484848A (zh) * 2018-02-27 2018-09-04 同济大学 一种缺氧响应的聚合物纳米胶束及其制备方法
CN108440684A (zh) * 2018-03-22 2018-08-24 华侨大学 一种NI-Cys-Alg自组装纳米载体及其制备方法和应用
CN108395489A (zh) * 2018-03-22 2018-08-14 华侨大学 一种2-硝基咪唑-半胱氨酸-海藻酸盐材料及其制备方法
KR20210003799A (ko) * 2018-04-13 2021-01-12 노쓰 캐롤라이나 스테이트 유니버시티 모발 성장 촉진을 위한 마이크로니들 패치의 사용
WO2019200081A1 (en) * 2018-04-13 2019-10-17 North Carolina State University Ros-responsive microneedle patch for acne vulgaris treatment
CN109464657A (zh) * 2018-11-26 2019-03-15 常州工程职业技术学院 一种嵌段共聚物载胰岛素控制释放的方法
CN109568567A (zh) * 2019-01-15 2019-04-05 武汉德丽福生物科技有限公司 一种微针减肥贴片及其制备方法
CN109771659A (zh) * 2019-02-25 2019-05-21 天津大学 一种乏氧响应性纳米药物载体及其制备方法和应用
CN110652494B (zh) * 2019-10-21 2021-09-28 南通大学 一种低氧响应聚氨基酸-peg立构载药胶束及其制备方法
CN110841065A (zh) * 2019-12-05 2020-02-28 福州大学 一种pH/低氧双响应释药协同光动力治疗的纳米复合物及其制备方法
CN115317437B (zh) * 2021-05-11 2023-09-08 中国科学院上海硅酸盐研究所 一种基于胆红素纳米材料的胰岛素递送微针及其制备方法
CN114376569B (zh) * 2022-01-19 2023-10-13 浙江大学 用于救治低血糖的载胰高血糖素可穿戴设备
CN114432243B (zh) * 2022-01-20 2023-08-29 华南师范大学 一种响应pH和葡萄糖的纳米载体及其应用
CN115120552A (zh) * 2022-06-22 2022-09-30 华中科技大学 一种微环境响应释药的多肽载药微针贴片、制备及应用
CN115531309B (zh) * 2022-09-29 2023-08-22 中国药科大学 一种肝靶向聚合物胶束递药系统及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
US8465468B1 (en) * 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
EP1610751A4 (en) * 2001-04-26 2006-05-24 Univ Texas AGENTE / LIGAND CONJUGATED THERAPEUTIC COMPOSITIONS, METHODS OF SYNTHESIS AND USE THEREOF
GB0116860D0 (en) 2001-07-10 2001-09-05 Univ Montfort Gel compositions
US20030135201A1 (en) * 2001-09-28 2003-07-17 Gonnelli Robert R. Microneedle with membrane
WO2003089506A1 (en) 2002-04-22 2003-10-30 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
JP4185423B2 (ja) 2003-09-09 2008-11-26 日本電信電話株式会社 電気化学バイオセンサの製造方法
US20080102114A1 (en) * 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
CN101227940A (zh) * 2005-07-25 2008-07-23 纳米技术维多利亚有限公司 微阵列装置
WO2007075388A2 (en) * 2005-12-15 2007-07-05 X-Cell Medical Incorporated Methods of locally treating and preventing cardiac disorders
WO2008011625A2 (en) * 2006-07-21 2008-01-24 Georgia Tech Researh Corporation Microneedle devices and methods of drug delivery or fluid withdrawal
CN101125086A (zh) * 2006-08-18 2008-02-20 刘胜 闭环自动控制胰岛素注射系统
KR101542433B1 (ko) * 2008-02-22 2015-08-06 도레이 카부시키가이샤 마이크로 입자 및 그 의약품 조성물
US7775357B2 (en) 2008-04-14 2010-08-17 Asp Rights Management Pty Limited Syringe disposal device
KR20100037389A (ko) * 2008-10-01 2010-04-09 연세대학교 산학협력단 다중 약물방출조절이 가능한 솔리드 마이크로구조체 및 이의 제조방법
JP5879126B2 (ja) * 2008-10-07 2016-03-08 ジン・トゥオＪＩＮ Ｔｕｏ 相転移ポリマーマイクロニードル
EP2391646B1 (en) 2009-01-28 2016-08-10 Smartcells, Inc. Crystalline insulin-conjugates
US20120046651A1 (en) 2009-04-17 2012-02-23 Uwe Beyer Medical device for glucose monitoring or regulation
CN102039000B (zh) * 2009-10-20 2015-08-26 苏州纳通生物纳米技术有限公司 一种透皮给药试剂盒
TWI545372B (zh) 2010-10-14 2016-08-11 Merck Patent Gmbh Liquid crystal display device
GB201101429D0 (en) * 2011-01-27 2011-03-16 Biocompatibles Uk Ltd Drug delivery system
CA2902762A1 (en) * 2012-02-17 2013-08-22 Massachusetts Institute Of Technology Glucose-responsive microgels for closed loop insulin delivery
CN105813652A (zh) * 2013-04-30 2016-07-27 麻省理工学院 用于糖尿病治疗的可注射纳米网络凝胶
KR102133889B1 (ko) * 2013-06-28 2020-07-14 엘지이노텍 주식회사 회로기판 및 상기 회로기판을 포함하는 조명장치
CN104353062A (zh) * 2014-11-21 2015-02-18 中国人民解放军南京军区福州总医院 一种胰岛素口服纳米制剂及其制备方法
SG11201708509YA (en) 2015-04-21 2017-11-29 Univ North Carolina State Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
US11141486B2 (en) 2015-10-23 2021-10-12 National University Corporation Tokyo Medical And Dental University Drug delivery device
CN108778248A (zh) 2016-02-19 2018-11-09 北卡罗来纳州立大学 与生理响应性微针递送系统有关的方法和组合物
WO2018085809A1 (en) 2016-11-07 2018-05-11 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery

Also Published As

Publication number Publication date
HK1245105A1 (zh) 2018-08-24
AU2016252738A1 (en) 2017-11-09
CN107530296B (zh) 2021-06-22
JP2018513874A (ja) 2018-05-31
US20220160841A1 (en) 2022-05-26
US11191815B2 (en) 2021-12-07
CO2017011422A2 (es) 2018-03-28
EP3285750B1 (en) 2020-10-21
PE20180325A1 (es) 2018-02-13
AU2016252738B2 (en) 2021-07-08
KR102624501B1 (ko) 2024-01-11
WO2016172320A8 (en) 2017-11-02
CL2017002652A1 (es) 2018-03-23
IL255155A0 (en) 2017-12-31
RU2719584C2 (ru) 2020-04-21
CN113350489A (zh) 2021-09-07
EP3285750A4 (en) 2018-12-12
BR112017022535A2 (pt) 2018-07-10
CA2983289C (en) 2023-10-03
CN107530296A (zh) 2018-01-02
JP6856546B2 (ja) 2021-04-07
KR20170138542A (ko) 2017-12-15
EP3795143A1 (en) 2021-03-24
AU2021204048A1 (en) 2021-07-08
US20180110841A1 (en) 2018-04-26
CA2983289A1 (en) 2016-10-27
MX2017013337A (es) 2018-04-20
RU2017139931A3 (es) 2019-09-16
MA54623A (fr) 2021-11-03
TN2017000439A1 (en) 2019-04-12
RU2017139931A (ru) 2019-05-21
NZ736578A (en) 2023-12-22
SG11201708509YA (en) 2017-11-29
WO2016172320A1 (en) 2016-10-27
PH12017501910A1 (en) 2018-03-05
EP3285750A1 (en) 2018-02-28
ECSP17073558A (es) 2018-05-31

Similar Documents

Publication Publication Date Title
DOP2017000239A (es) Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
Monfrecola et al. Mammalian target of rapamycin, insulin resistance and hidradenitis suppurativa: a possible metabolic loop.
CL2015002680A1 (es) Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos
CL2011000899A1 (es) Compuestos arilicos, moduladores de la actividad gpr120 en una celula; composicion farmaceutica; y uso de dichos compuestos para el tratamiento de la diabetes tipo i, ii, sindrome metabolico, estimular la produccion de insulina, bajar el nivel de glucosa en la sangre.
MX2015012433A (es) Matriz de microestructura para suministro de agentes activos.
AR069704A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
BR112013032265A2 (pt) métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
BR112014013151A2 (pt) dispositivo de microagulhas incluindo um agente terapêutico peptídeo e um aminoácido, métodos para produzir e usar o dispositivo
BR112018003882A2 (pt) material auxiliar para proporcionar eluição de fármaco de vasos
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
BR112016002646A2 (pt) dispositivos e métodos de entrega de fármaco de múltiplas unidades
WO2015105981A3 (en) Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment
PH12015501931A1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
PE20191836A1 (es) Compuesto de insulina acilada
BR112013027010A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos
PH12015502556A1 (en) Modified release formulation
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
AR109946A1 (es) Páncreas artificial
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
EA202090988A1 (ru) Способы лечения синдрома фелан-макдермид с помощью дибензодиазепинонов фарнезила
BR102018010523A2 (pt) peptídeo, composição farmacêutica compreendendo o mesmo e uso
TH172399A (th) การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน